Board Of Directors
Executive Partner and Founder
Chairman of the Board
Mike has 28 years of operating and management experience, most recently at Quintiles an Executive Vice President. In this role, Mike was responsible for Quintiles’ global operations in Health Engagement and Communications, Legal and Risk Management, Real Estate and Facilities, Human Resources as well as Security. He was also the Chairman of the company’s European, Middle East, Africa and Latin American management board, in which he was accountable for the organic and inorganic growth strategies of the regions. Mike joined Quintiles in July of 2003 following 10 years at Charles Schwab Corp., where he was Senior Vice President of Human Resources for the company’s global retail and internet organisations. Mike sits on the boards of Oxford Cancer Biomarkers Ltd., HUYA Bioscience International and the Multiple Myeloma Research Foundation. He holds a bachelor’s degree in Behavioural Sciences from The Ohio State University.
Lori Tauber Marcus
Vice Chairman of the Board
Lori Marcus is an independent board director and the founder of Courtyard Connections – an advisory firm focused on Marketing and Leadership in the consumer goods, retail, foodservice, and consumer electronics industries.
Most recently, Lori was Chief Global Brand and Product Officer at Keurig Green Mountain. With more than 30 years of broad-based marketing and general management experience, Lori was responsible for global brand and product management for the Keurig system of innovative coffee brewers and beverages. She also drove the development of the groundbreaking cold beverage system, Keurig Kold™, partnering with world-class companies like The Coca-Cola Company & Dr. Pepper Snapple Group. During her tenure at Keurig Green Mountain, she also led the company’s global marketing efforts and all aspects of e-commerce, digital/social media, marketing insights, and graphic design.
Previously, Lori was the SVP, Chief Marketing Officer of The Children’s Place Retail Stores. Prior to that, she spent 24 years with PepsiCo in marketing positions of increasing responsibility, culminating in her appointment as Senior Vice President, Marketing Activation for PepsiCo Beverages, North America. Her previous PepsiCo experience included responsibility for global strategic initiatives, product innovation, customer marketing, brand marketing, and strategy in their beverage and foodservice divisions. She earned her BS degree in Marketing from the Wharton School of Business at the University of Pennsylvania. Ms. Marcus currently serves on the CMO advisory board for VentureBeat and is a board advisor to Carrington Farms.
MMRF and MMRC
Kathy Giusti is the Founder and currently sits on the Board of Directors of the MMRF and the MMRC. She is also a multiple myeloma patient. Kathy has led the MMRF in establishing collaborative research models in the areas of clinical trials, genomics, and tissue banking. These models have dramatically accelerated the pace at which lifesaving treatments are brought to patients and improved our understanding of the disease’s biological underpinnings. Today, Kathy is widely recognized as a champion of open-access data sharing and a strong advocate for patient engagement, not only in their cancer care, but as part of the research and drug development process. Kathy’s visionary leadership has earned her several prestigious awards and recognitions. Most recently, she was ranked #19 on Fortune Magazine’s Worlds’ 50 Greatest Leaders. In 2013, she was named an Open Science Champion of Change by the White House. In 2011, she was named to the TIME 100 List of the world’s most influential people. Kathy also has been featured on several media outlets, including CNN Money, NBC Nightly News, and the Today Show, as well as in the New Yorker, the New York Times, and The Wall Street Journal. Kathy serves on the President’s Council of Advisors on Science and Technology, the Executive Management Committee of Stand Up to Cancer and the Harvard Business School Healthcare Advisory Board. Kathy received her MBA in general management from Harvard Business School and graduated from the University of Vermont. She holds an honorary Doctorate from the University of Vermont.
Kenneth Anderson, MD
Jerome Lipper Multiple Myeloma Center,
Dana-Farber Cancer Institute
Dr. Anderson graduated from Johns Hopkins Medical School. He trained in internal medicine at Johns Hopkins Hospital and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School and serves as Chief of the Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at the Dana-Farber Cancer Institute. He received the Waldenstrom’s Award in 2003 for his translational research directed to the development of novel therapeutics targeting the myeloma cell in its microenvironment and is a Doris Duke Distinguished Clinical Research Scientist. In addition to serving on the Board of Directors of the MMRF, Dr. Anderson serves as Chairman of the MMRF’s Scientific Advisory Committee, Chairman of the Multiple Myeloma Research Consortium, and Chairman of the National Comprehensive Cancer Network’s Multiple Myeloma Clinical Practice Guidelines Committee.
Karen E. Andrews
Senior Vice President and General Counsel
March of Dimes
Karen E. Andrews is currently SVP and General Counsel for the March of Dimes. Previously Karen was the General Counsel and Corporate Secretary of BBDO Worldwide, Inc. where she was responsible for the management of the legal activities of over 150 individual operating units throughout the world. Prior to joining BBDO Worldwide, Ms. Andrews was Associate General Counsel and Director of Television Business Affairs at Time Inc. Ms. Andrews began her career in law as a Litigation Associate at the New York law firm of Weil, Gotshal & Manges where she specialized in Entertainment Litigation. Ms. Andrews graduated cum laude from the University of Vermont with a Bachelor of Science degree in biology and earned her law degree, cum laude, from Temple School of Law. Ms. Andrews is a member of the American Bar Association and the New York State Bar Association. In 1998, Ms. Andrews co-founded the Multiple Myeloma Research Foundation with Kathy Giusti.
William K. Bowes, Jr.
US Venture Partners
Founding partner Bill Bowes has seen a lot of change since USVP’s inception in 1981 – in the venture community, in the Valley, in the world. But some important things remain the same; namely, the passion of entrepreneurs: “It’s the entrepreneurs that keep this business new and fresh, every day,” says Bill. A venture capitalist in the Bay Area for nearly 50 years, Bill founded and helped to build USVP to what it is today. His belief that venture capitalists should guide companies based on real-world experience continues to set the tone at USVP: “We’ve always put our emphasis on the operational experience of our team,” notes Bill. “The partners here can say to entrepreneurs ‘we’ve been where you’re going’ and really mean it.”
Bill was the founding shareholder of Amgen and was its first Chairman and Treasurer. Prior to founding USVP, he’d already had success as a venture capitalist with companies like Cetus, Raychem (where he served on the board from 1961 until the late 1970s), and Dymo Industries. Bill had previously been Senior Vice President and Director of Blyth Eastman Dillon & Company, where he worked from 1953 to 1978 and was a consultant to Blyth Eastman Paine Webber from 1978 to 1980. At USVP, Bill led the firm’s investments in Advanced Cardiovascular Systems, Applied Biosystems, Devices for Vascular Intervention, Glycomed, Sun Microsystems and Ventritex. Currently Bill is on the board of Xoma Corporation.
Today Bill devotes much of his time to education and medical research. He is on the executive committee of the San Francisco Conservatory of Music and recently retired as Board Chairman of The Exploratorium, San Francisco’s exemplary interactive museum of the sciences. He also serves on the Board of the Asian Art Museum, Grace Cathedral and the Hoover Institution.
Having focused his investment career largely in the medical industry, Bill remains involved through some of his nonprofit work. He is on the Board of Directors of the UCSF Foundation and was Chairman of the Mission Bay Capital Campaign. He serves on the Advisory Committees of Bio-X, the Institute for Systems Biology, QB3 and Harvard Partners Center for Genetics and Genomics – each dedicated to furthering interdisciplinary medical research. He is on the visiting committee at the Harvard Business School. Bill holds a B.A. in Economics from Stanford University, an M.B.A. from Harvard University and served in the U.S. Army infantry in the South Pacific and Japan during and after World War II
Tom was appointed President of SAC Capital in July 2008. He joined SAC in October 1999 as Chief Operating Officer. Prior to joining SAC, Tom was President of Investment Management Services, Inc (“IMS”) from 1996 to 1999. He joined Moore Capital /IMS in 1993 and served as its Director of Trading Operations and then Vice President until IMS split off from Moore in 1995. Tom joined Moore Capital /IMS from Goldman Sachs Trust Company, where he was a Vice President with responsibilities for daily operations, technology, and client services. From 1986 to 1993, Tom was in the operations and equity divisions of Goldman, Sachs & Co., becoming Vice President in 1991. He retired from SAC December 2014.
Eugene P. Grisanti
Retired Chairman, President and CEO
International Flavors & Fragrances, Inc.
Eugene P. Grisanti is the former Chairman, President and CEO of International Flavors & Fragrances, the world’s largest flavor and fragrance company, a position he held for fifteen years, after serving as Senior Vice-President, General Counsel and other executive positions. He was a corporate attorney with the firm Fulton, Walter and Halley in New York City prior to joining IFF. Mr. Grisanti was elected to The Rockefeller University Board of Trustees in 1991, served as Chairman of The Rockefeller University Hospital Committee, and was elected Trustee Emeritus in 2000. Mr. Grisanti is Managing Director of The Metropolitan Opera, Vice-Chairman of The New York Botanical Garden, Chairman Emeritus of The New York City Ballet, and Director Emeritus of Lincoln Center for the Performing Arts. He is also a member of the Boards of the Ambrose Monell Foundation and the G. Unger Vetlesen Foundation. Eugene Grisanti received an A.B. from Holy Cross College, an LL.B. cum laude from Boston University, and an LL.M. from Harvard Law School.
David L. Lucchino
Chief Executive Officer
David Lucchino is the CEO of Entrega, a biotechnology company co-founded by MIT Institute Professor Robert S. Langer, Sc.D and PureTech Ventures. David also holds an Entrepreneur in Residence position at PureTech Ventures.
Previously David was the Chief Executive Officer and President of Semprus BioSciences until its acquisition by Teleflex Medical, Inc. (NYSE: TFX). He then served as a Vice President executing the post-M&A integration plan for eighteen months. David co-founded Semprus BioSciences while attending the Massachusetts Institute of Technology with Robert S. Langer, Sc.D.
Under his stewardship, Semprus BioSciences grew from two to 50 employees, secured $28.5 million in venture capital financing as well as $8.4 million in federal funding and received approval from the FDA and European regulators for its first medical device product within five years of the company founding.
Prior to co-founding Semprus, David was a Senior Associate at Polaris Venture Partners, a multibillion dollar venture capital fund based in Boston. Previously, David co-founded and served as Managing Director of LaunchCyte, an investment firm that specializes in acquiring and developing biomedical intellectual property.
David began his career as a technology marketing executive. He earned his MBA as an Alfred P. Sloan Fellow at the Massachusetts Institute of Technology. He also earned a Master of Science degree from Syracuse University and a Bachelor of Arts degree from Denison University.
David is a member of the Board of Directors of the Massachusetts Biotechnology Council (Mass Bio), where he serves on the executive committee. He is a Trustee of Mt. Auburn Hospital, a Harvard Medical School facility, where is Chairman of the Audit Committee, Babson College and the Multiple Myeloma Research Foundation.
Outside the office, David is active with the National Outdoor Leadership School (NOLS), where he was part of an expedition that climbed Alaska’s Mt. McKinley, North America’s tallest mountain, and spent 95 days living in the Rocky Mountains as part of a leadership training program. He most recently rafted down Idaho’s “River of No Return,” the Salmon River, with NOLS. David has participated as part of the Boston Red Sox “Team 9” in the Pan-Mass Challenge, the annual two-day bike ride that raises funds for adult and pediatric cancer care and research at Dana-Farber Cancer Institute.
W. Dana LaForge
Brera Capital Partners, LLC
Dana LaForge is a Partner at Brera Capital Partners, a private equity fund, and the Founder and Managing Partner of Colonnade Financial Group, a private equity services firm. Prior to Brera and Colonnade, Dana was head of Financial Institutions Investment Banking and Chief of Staff of Banking and Capital Markets at Deutsche Bank and its predecessor companies. Earlier in his career, he was a bond trader and founded the Mortgage Finance Group. Dana has served on numerous portfolio company boards and is the Chairman of GAB Robins NA. He was one of the earliest Directors of the Multiple Myeloma Research Foundation joining the Board in 1999 and helping guide the Foundation from start up through today serving as the organization’s only Chairman since being elected in 2003. Dana earned a BS from Washington and Lee University and an MBA from Harvard Business School. He lives in New York City with his wife, Kathleen McCabe and their two daughters.
Joel S. Marcus
Chairman, Chief Executive Officer and Founder
Alexandria Real Estate Equities, Inc.
Joel S. Marcus has served as Chairman of the Board of Directors since May 2007, Chief Executive Officer since March 1997, President since February 2009, and a director since the Company’s inception in 1994. Mr. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994, Alexandria Venture Investments in 1996, and the annual Alexandria Summit in 2011. From 1986 to 1994, Mr. Marcus was a partner at the law firm of Brobeck, Phleger & Harrison LLP, specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions. From 1984 to 1994, he also served as General Counsel and Secretary of Kirin-Amgen, Inc., a joint venture which financed the development of, and owned patents to, two multi-billion dollar genetically engineered biopharmaceutical products. Mr. Marcus was formerly a practicing certified public accountant and tax manager with Arthur Young & Co. specializing in the financing and taxation of real estate and real estate investment trusts (REITs). He received his undergraduate and Juris Doctor degrees from the University of California, Los Angeles. Mr. Marcus serves on the boards of the Accelerator Corporation, of which he was one of the original architects and co-founders, Foundation for the National Institutes of Health (FNIH), Intra-Cellular Therapies, Inc., Multiple Myeloma Research Foundation (MMRF), and the Partnership for New York City. Mr. Marcus received the Ernst & Young 1999 Entrepreneur of the Year Award (Los Angeles – Real Estate).
Mr. McDougall is Partner at PricewaterhouseCoopers Health Sciences Practice, where he provides services to academic medical centers, bioscience companies, pharmaceutical companies, research universities, colleges, health systems, and other research organizations. His practice provides a broad range of research business and compliance services, including strategic and business planning, financial analysis, research compliance, clinical research operations improvement, and information systems implementation services. In addition, his practice provides support services to the entire research continuum, from grant-funded basic science research, to translational research and clinical trials, including a dedicated group focusing on Clinical Research Consulting services.
William S. McKiernan
Former Chair and CEO
William McKiernan is the Chairman and Chief Executive Officer of CyberSource Corporation. Prior to founding CyberSource, Mr. McKiernan was President and Chief Operating Officer of McAfee Associates, now Network Associates; Mr. McKiernan held this position during the company’s initial public offering. Before joining McAfee, Mr. McKiernan was Vice President of Princeton Venture Research, Inc. and held management positions at ROLM/IBM. In addition to serving on the Board of Directors of the MMRF, Mr. McKiernan is the West Coast Chairman of the Boston College Technology Council. Mr. McKiernan holds a Bachelor of Science from Boston College and an MBA from Harvard Business School.
Charles B. Ortner
Proskauer Rose LLP
Charles B. Ortner is a Partner at the New York-based Proskauer Rose LLP law firm, where he represents many of the world’s leading recording artists, songwriters, record producers, music publishers and record companies in litigation, as well as a counselor and strategic advisor. Mr. Ortner also serves as National Legal Counsel to the National Academy of Recording Arts & Sciences, Inc. (the Grammy Award organization). Previously, Mr. Ortner served as an Aide to Mayor John V. Lindsay of New York City, and as an Assistant to United States Attorney Whitney North Seymour, Jr. in the Southern District of New York. In addition to serving on the Board of Directors of the MMRF, Mr. Ortner was a member of the Board of Trustees of the T.J. Martell Foundation for Leukemia, Cancer and AIDS Research, and currently serves as the President of the Kanye West Foundation, an organization dedicated to using music education to combat the drop out problem faced by inner city schools. Along with his two children, Mr. Ortner established the Jane Ortner Multiple Myeloma Research Fellowship at New York Weill Cornell Medical Center. Mr. Ortner received his bachelor’s degree from Washington University in St. Louis and received his law degree from Brooklyn Law School
David R. Parkinson, MD
Chairman of the Clinical Advisory Board
From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a South San Francisco-based venture-financed biotechnology company developing technologies to enable personalized medicine and more efficient drug development in cancer and autoimmune diseases. Before joining Nodality, Dr. Parkinson was Senior Vice President, Oncology R&D, at Biogen Idec, overseeing oncology discovery research efforts and the development of the oncology pipeline. Previously he had served tenures as Vice President and Head of the Oncology Therapeutic Area at Amgen and Vice President and Head of Global Clinical Oncology Development at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec®, Femara®, Zometa®, Kepivance®, and Vectibix®. He received his M.D. from the University of Toronto Faculty of Medicine in 1977, with Internal Medicine and Hematology/Oncology training at McGill University and at New England Medical Center. Dr. Parkinson has authored more than 100 peer-reviewed scientific papers, and is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee as well as a recipient of the FDA’s Cody Medal.
Marie Pinizzotto, MD
President and CEO
Carol A. Ammon Foundation
Marie Pinizzotto, M.D., MBA, is currently the president and CEO of the Carol A. Ammon Foundation, a foundation focused on health care, education and children with disabilities. She was also the president of Drug Safety Solutions, L.L.C., a Pharmacovigilance and Risk Management consulting company whose main focus is pharmacovigilance and risk management for narcotics and other high risk drugs. Prior to starting her consulting firm she worked at Endo Pharmaceuticals Inc. where she was Senior Director of the Global Safety and Pharmacovigilance department. In this role she was responsible for pharmacovigilance of all Endo products, investigational as well as marketed. Marie was responsible for the safety components in following disciplines as well; Clinical Research, Medical Affairs and Clinical Education and Development. In addition, she led the Risk Management Team and was responsible for the creation and implementation of Endo’s risk management programs.
Before working at Endo, she was a Senior Director of Report Evaluation and Safety Surveillance for the Women’s Health Division and Consumer Products at Wyeth. In the Women’s health arena she was responsible for the development of the risk management and Pharmacovigilance plans for hormone replacement products. She also participated and chaired safety reviews of adverse events from clinical trials as well as marketed products.
Dr. Pinizzotto received her B.S in Chemistry, magna cum laude, from the University of Pittsburgh, Pittsburgh Pennsylvania and her medical degree from Jefferson Medical College in Philadelphia. She completed her residency at The Medical Center of Delaware, where she practiced obstetrics and gynecology for nine years. She still maintains privileges at the hospital. Most recently, Dr. Pinizzotto earned her MBA at the University of Delaware where she maintained a 4.0 GPA.
Currently Dr. Pinizzotto is a trustee of Christiana Care Hospital and a member of the Quality and Safety Committee. She is the named Chair, The Marie E. Pinizzotto, MD Chair of Academic Affairs, at Eisenhower Medical Center, Rancho Mirage, California. Dr. Pinizzotto sits on the boards of the following non-profit organizations: The Pregnancy Foundation, The Carol A. Ammon Foundation, which she is President and CEO. In additions she participates on the following two advisory boards: Scientific steering committee on Personalized Medicine for the Multiple Myeloma Research Foundation and Pediatric Disease Research for The Mario Batali Foundation. In addition she has been on the board for SOAR and Synova Pharmaceutical. She is also currently volunteering her time with Eisenhower Medical in Rancho Mirage, California as they embark on the development of a medical residency program and being considered as a trustee for the institution.
Fox Rothschild LLP
Michael Reinert is a leading music industry attorney who most recently served as Executive Vice President of Business & Legal Affairs for the Universal Motown Republic Group, a division of UMG Recordings, Inc. In that position, he had the pleasure of working with great talent such as Stevie Wonder, Elton John, Taylor Swift, Amy Winehouse, Lil Wayne, Nelly, Jack Johnson and many other platinum selling acts. Prior to joining Universal ten years ago, Michael was the Vice President of Business & Legal Affairs for PolyGram Records, handling those duties for the legendary Verve Records label and Mercury Nashville Records where he worked with the likes of Herbie Hancock and Shania Twain. Michael started his career in private practice representing many artists, producers and writers before joining the corporate ranks. Michael was an Adjunct Professor of Law at his alma mater, The Benjamin Cardozo School of Law of Yeshiva University, for ten years teaching Contract Drafting and Negotiation in the Music Industry. He has been a contributing editor to the Practicing Law Institute volumes on the same subject and continues to lecture at various schools and seminars around the country. He currently serves as the Chairman of the Entertainment Law Initiative of the Grammy Foundation, a division of the National Academy of Recording Arts and Sciences, which focuses on legal education programs for aspiring entertainment attorneys. Michael attended the Horace Mann School for Boys in Riverdale and Tulane University in New Orleans, a place he considers his second home. He lives in Manhattan with his wife of 30 years, Karen. They have a daughter and two beautiful grandchildren.
Steven Shak, MD
Co-Founder, Chief Scientific Officer
Dedicated to optimizing cancer treatment outcomes and bringing the patient voice into product development, Steve Shak, M.D. has served as the Co-Founder, Chief Scientific Officer since 2012 and was the Chief Medical Officer from 2000 – 2013. Under Steve’s leadership Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX® breast cancer and colon cancer assays and has maintained an 80% product development success rate. Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding Genomic Health in 2000, Steve served for 14 years in various roles in Discovery Research and Medical Affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Steve led the clinical team that gained approval for Herceptin®, a targeted biologic treatment for breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin®. In addition, Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis. Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Steve holds a Bachelor of Arts degree in Chemistry from Amherst College and an M.D. from New York University School of Medicine, and completed his post-doctoral training at University of California, San Francisco.
Chief Financial Officer
Meryl Zausner is the Chief Financial Officer of Novartis Corporation and a member of the company’s Executive Committee. In this position, Ms. Zausner oversees Investor Relations, Controlling, Treasury, Cash Management, Tax and Risk Management across all of the Novartis divisions based in the US, as well as the financial management of the Novartis benefit plans.
Ms. Zausner has worked in the Consumer Products and Pharmaceutical industries for 28 years. Previously, she was Vice President and CFO of Novartis Oncology. In addition to her responsibilities as CFO, Ms. Zausner chaired the Novartis Pharmaceuticals 2006 & 2007 Global Diversity Council, of which she was a founding member. She was also a founding member of the U.S. EWIN (Empowering Women to Impact Novartis) Initiative now with over 1,500 members. In 2007, she was named (HBA) Healthcare Businesswomen Association’s Woman of the Year.
Before joining Novartis, Ms. Zausner held a variety of positions with the Colgate Palmolive Company and spent 3 years working in Public Accounting. She has degrees in Economics and Accounting from the University at Albany as well as her CPA in New York.
She is a member of the HBA Advisory Board, Corporate Council member of Deirdre House, which is an advocacy center for child victims of abuse or neglect, member of the Audit and Finance Subcommittee of PhRMA, Gilda’s Club 2009 Red Door Honoree and Board member of the T.J. Martell Foundation for Cancer Research.